Neuren Pharmaceuticals company profile
Company profile
Neuren Pharmaceuticals has 8 employees and is headquartered in Hawthorn East, Australia.
With eight employees and revenue of AUD 64.6 million in the fiscal year ended December 2025, Neuren Pharmaceuticals develops drugs for neurological disorders. It develops and commercializes DAYBUE (trofinetide) for Rett syndrome in adults and in patients aged 2 years and older, and runs a Phase 2 trial for Fragile X syndrome. Its NNZ-2591 compound has completed Phase 2 testing for Phelan-McDermid syndrome, is in Phase 2 for Angelman and Pitt Hopkins syndromes, and is in preclinical stage for Prader-Willi syndrome, hypoxic ischemic encephalopathy and SYNGAP1.
Net profit for the same fiscal year was AUD 30.4 million, while revenue fell 70.2% compared with the prior fiscal year. The company was incorporated in 2001 and has its headquarters in Hawthorn East, Australia, where it employs eight people.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Headquarters
- 117 Camberwell Road, 3123, Hawthorn East
- Employees
- 8
- Chief executive
- Jonathan Pilcher
- Founded
- 2001
- Fiscal year
- January - December
- Listing
- NEU · ASX
- Indices
- S&P/ASX 200
- Currency
- AUD
- ISIN
- NZNEUE0001S8
- Website
- neurenpharma.com
Neuren Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Neuren PharmaceuticalsNEU | Australia | $1.83B | 8 | 19.9% | 144.0 |
| MesoblastMSB | Australia | $1.48B | 108 | -42.6% | — |
| InSilico Medicine Cayman TopCo3696 | Hong Kong SAR China | $2.59B | 333 | -6.9% | — |
| Telix PharmaceuticalsTLX | Australia | $2.92B | 1,120 | 6.2% | 92.3 |
| Metis TechBio7666 | Hong Kong SAR China | $1.11B | 150 | -131.2% | — |
| 3SBio1530 | Hong Kong SAR China | $4.56B | 6,068 | 60.3% | 3.90 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
